A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells-Reference-Cited by-同舟云学术

A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells

Published:2023-06-14 Issue:1 Volume:15 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Tan Xiaoding¹,Fang Peng²,Li Kaiying²,You Meng²,Cao Yuxia²,Xu Hui²,Zhu Xiaohong²,Wang Lu²,Wei Xin²,Wen Haiying²,Li Wendi²,Shi Lei²,Sun Xiaowei²,Yu Dongan²,Zhu Huikai²,Wang Zhenzhen²,Liu Datao²,Shen Hui³,Zhou Wei²,An Maomao¹^ORCID

Affiliation:

1. Department of Pharmacology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, The People’s Republic of China

2. Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd, Taizhou, Jiangsu Province, The People’s Republic of China

3. Department of Clinical Laboratory Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, The People’s Republic of China

Funder

The Shanghai Natural Science Foundation

The Shanghai Science and Technology Support Program

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2023.2220466

Reference31 articles.

1. Antibody–drug conjugates in solid tumors: a look into novel targets

2. Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies